Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study

8010 Background: In the first phase of BATTLE clinical study, 72 pts with advanced, previously treated NSCLC were characterized into one of four biomarker groups (BGs) based on their pre-treatment tumor biomarker profile. BGs included the following: EGFR (mutation & gene copy number), angiogenesis (VEGF and VEGFR-2 by IHC), K-ras/B-raf mutations and RXR/Cyclin D-1 (IHC and gene copy number). We performed exploratory analysis of plasma levels of 59 C/AFs to investigate potential correlation with pathway activation from pretreatment tumor specimens. Methods: 62/72 pts consented to the optional blood collection for C/AF analysis. We used multiplex bead assays to measure 53 plasma C/AFs, including VEGF, basic FGF, HGF, E-selectin, MMP-9, multiple chemokines and interleukins (IL). Total and free IGF-1, IGFBP-3, osteopontin (OPN) and sVEGFR-1&2 were measured by ELISA. To evaluate the association between plasma C/AFs and pretreatment tumor markers, Wilcoxon test was performed. Results: A significantly higher sco...